Literature DB >> 10728961

Clinical and cost comparison of ibutilide and direct-current cardioversion for atrial fibrillation and flutter.

D K Murdock1, G T Schumock, J Kaliebe, K Olson, A J Guenette.   

Abstract

The clinical effectiveness and cost to convert recent-onset atrial fibrillation or flutter to sinus after 3 to 4 weeks of anticoagulation with intravenous ibutilide was compared with direct-current cardioversion. The low success rate with ibutilide made direct-current cardioversion the more clinical and cost-effective method to restore sinus rhythm.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10728961     DOI： 10.1016/s0002-9149(99)00782-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  4 in total

1.  Vernakalant versus ibutilide for immediate conversion of recent-onset atrial fibrillation.

Authors:  I Vogiatzis; E Papavasiliou; I Dapcevitch; S Pittas; E Koulouris
Journal:  Hippokratia       Date:  2017 Apr-Jun       Impact factor: 0.471

2.  Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation.

Authors:  Craig I Coleman; James S Kalus; C Michael White; Anne P Spencer; James P Tsikouris; Jenny O Chung; Kenneth W Kenyon; Martin Ziska; Jeffrey Kluger; Prabashni Reddy
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 3.  Cost effectiveness of therapies for atrial fibrillation. A review.

Authors:  M P Teng; L E Catherwood; D P Melby
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

4.  Atrial Flutter.

Authors:  Ashok Garg; Gregory K. Feld
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.